Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shinichi Tate is active.

Publication


Featured researches published by Shinichi Tate.


British Journal of Obstetrics and Gynaecology | 2003

Early invasive cervical adenocarcinoma: its potential for nodal metastasis or recurrence

Yasuo Hirai; Nobuhiro Takeshima; Shinichi Tate; Futoshi Akiyama; Reiko Furuta; Katsuhiko Hasumi

Objective To investigate the potential for nodal spread or recurrence in patients with early invasive cervical adenocarcinoma. The possible application of the International Federation of Gynecology and Obstetrics (FIGO) classification (1994) to this variant was also examined.


International Journal of Cancer | 2003

Ectopic chromosome around centrosome in metaphase cells as a marker of high-risk human papillomavirus-associated cervical intraepithelial neoplasias.

Reiko Furuta; Yasuo Hirai; Katsuyoshi Katase; Shinichi Tate; Tokuichi Kawaguchi; Futoshi Akiyama; Yo Kato; Kazuki Kumada; Tsuyoshi Iwasaka; Nobuo Yaegashi; Koji Kanazawa; Hiroyuki Yoshikawa; Tomoyuki Kitagawa

This report describes the appearance of ectopic chromosome around centrosome (ECAC) in metaphase cell nuclei of high‐risk HPV‐associated cervical neoplasms. ECAC are clearly visible on HE‐stained sections as a tiny (approx. 0.7 μ), round, dark structure or an aggregate of filamentous chromosome, often symmetrical at bilateral centrosomes. They appear in CINs from an early stage (CIN I), with the highest incidence in HPV16‐associated CIN II–III (75%), and are less common in HPV‐related invasive carcinomas (21%) and in lesions associated with high‐risk HPV types other than 16. Rates for ECAC‐positive nuclei in metaphase preparations (ECAC rate) for each lesion ranged 3.6–30%, the average being 14.5%. ECAC appeared very rarely in CINs associated with intermediate‐risk HPVs and was never encountered in HPV6/11‐induced condylomas or HPV‐unrelated neoplasms in other organs. ECAC may be morphologic evidence of HPV‐induced chromosomal instability working as a background mechanism in cervical carcinogenesis and also a useful marker for the histopathologic differentiation of high‐risk CINs.


Gynecologic Oncology | 2018

Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava

Ayumu Matsuoka; Shinichi Tate; Kyoko Nishikimi; Makio Shozu

Objective Double inferior vena cava (IVC) is present in 1.0%–3.0% of the general population and can create clinical problems [1,2]. This anomaly is classified according to the presence and pattern of an interiliac vein; 23% of double-IVC cases do not have an interiliac vein, and variations exist in those with one [3]. Fewreports on retroperitoneal lymphadenectomy in patients with a double IVC exist. Herein, we show retroperitoneal lymphadenectomies in two patients with different double IVC classifications. Methods We performed an interval debulking surgery, including retroperitoneal lymphadenectomy, in two cases of advanced ovarian cancer with double IVC. The retroperitoneal lymphadenectomy procedure was the same as that for patients with normal IVC. Case 1 involved a 53-year-old female having a double IVC without an interiliac vein. Case 2 involved a 51-year-old female having a double IVC with an interiliac vein from the right common iliac vein to the left IVC. Preoperative enhanced computed tomography revealed double IVC flow pattern in both cases; however, the presence of the interiliac vein in case 2 remained unrecognized. Results Lymphadenectomy in case 1 was without complications. In case 2, major bleeding from the interiliac vein occurred during lymphatic tissue removal from the front of the sacral region. The bleeding was difficult to stop, and was finally stopped using Tacho Sil®. We then completed lymphadenectomy. Conclusions During retroperitoneal lymphadenectomy in patients with a double IVC, it is important to determine the presence of an interiliac vein. Furthermore, its flow pattern should be considered with care.


The Journal of the Japanese Society of Clinical Cytology | 2000

Comparative analysis of endometrial cytology between endometrial serous adenocarcinoma and ovarian or fallopian tubal serous adenocarcinoma.

Reiko Nemoto; Yuko Sugiyama; Yuji Arai; Yasuo Hirai; Wataru Sato; Shinichi Tate; Yoshiyuki Okano; Masafumi Tsuzuku; Katsuhiko Hasumi

目的: 子宮内膜細胞診において, 子宮体部の漿液性腺癌と卵巣, 卵管の漿液性腺癌の鑑別を目的に, 細胞学的検討を行った.方法: 1977年~1998年の21年間, 癌研究会附属病院にて手術を施行し, 確定診断された子宮体部漿液性腺癌32症例と, 子宮内膜細胞診陽性であった卵巣, 卵管原発の漿液性腺癌21症例を対象とした.子宮内膜細胞診はすべて増淵式吸引スメア法で採取した.結果: 細胞標本が見直し可能であった42例中, 子宮体部原発の26症例と, 卵巣, 卵管原発の16症例 (うち, 卵管癌7例) について細胞像を比較した.子宮体部漿液性腺癌では背景が腫瘍性 (92%) で, 正常子宮内膜細胞の混入は少なく, 腫瘍細胞集塊の辺縁が鋸歯状不整 (85%) な症例が多くみられた.一方, 卵巣, 卵管の漿液性腺癌では背景がきれい (81%) で, 正常子宮内膜細胞が多数混在しており, 腫瘍細胞集塊の辺縁が平滑 (94%) な症例が多くみられた.また, 腫瘍細胞集塊の構成細胞数は子宮体部漿液性腺癌では125.8±9.4個, 卵巣および卵管の漿液性腺癌では54.6±4.9個であり, 子宮体部漿液性腺癌の方が有意に多かった (t-test; p=0.000).結論: 子宮体部漿液性腺癌と卵巣, 卵管原発の漿液性腺癌は, 子宮内膜細胞診上個々の腫瘍細胞形態のみでは, 区別が困難であるが, 背景や集塊の出現形式, 正常子宮内膜細胞の混在に注目すると区別が可能と考えられた.


Gynecologic Oncology | 2005

CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma

Shinichi Tate; Yasuo Hirai; Nobuhiro Takeshima; Katuhiko Hasumi


The Journal of the Japanese Society of Clinical Cytology | 2000

Cytological findings of extrauterine cancers detected by endometrial aspiration cytology.

Naotake Tanaka; Yasuo Hirai; Nobuhiro Takeshima; Shinichi Tate; Shigero Okano; Atsuko Minami; Masafumi Tsuzuku; Kazuhiro Yamauchi; Souei Sekiya; Katsuhiko Hasumi


The Journal of the Japanese Society of Clinical Cytology | 1999

Perivascular structures in inprint-cytologic features of endometrial stromal sarcoma.

Shinichi Tate; Hideaki Iwasaki; Yasuo Hirai; Norihiro Furuta; Hiroshi Suzuki; Hiroshi Iura; Reiko Nemoto; Bin Takeda


Gynecologic Oncology | 2018

Successful retroperitoneal lymphadenectomy for double inferior vena cava with preoperative assessment using contrast-enhanced and three-dimensional computed tomography

Ayumu Matsuoka; Shinichi Tate; Kyoko Nishikimi; Makio Shozu


Gynecologic Oncology | 2018

Left cardiophrenic lymph node resection for advanced ovarian cancer with adhesion to the thoracic cavity

Ayumu Matsuoka; Shinichi Tate; Kyoko Nishikimi; Makio Shozu


Gynecologic Oncology | 2018

Efficacy of soft coagulation in retroperitoneal lymphadenectomy for ovarian cancer

Ayumu Matsuoka; Shinichi Tate; Kyoko Nishikimi; Makio Shozu

Collaboration


Dive into the Shinichi Tate's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Katsuhiko Hasumi

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Nobuhiro Takeshima

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Futoshi Akiyama

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Reiko Furuta

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge